Qiagen (QGEN) Releases Q4 2018 Earnings Guidance

Qiagen (NASDAQ:QGEN) issued an update on its fourth quarter 2018 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.39-0.40 for the period, compared to the Thomson Reuters consensus estimate of $0.42. The company issued revenue guidance of $420.714-424.683 million, compared to the consensus revenue estimate of $419.23 million.Qiagen also updated its FY 2018 guidance to $1.33-1.34 EPS.

Shares of QGEN stock traded down $0.43 during trading hours on Monday, reaching $33.54. The company’s stock had a trading volume of 1,145,506 shares, compared to its average volume of 984,877. Qiagen has a one year low of $30.20 and a one year high of $39.45. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69.

Qiagen (NASDAQ:QGEN) last issued its quarterly earnings data on Tuesday, July 31st. The company reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.01. The firm had revenue of $377.20 million for the quarter, compared to analyst estimates of $376.89 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. On average, equities research analysts expect that Qiagen will post 1.34 earnings per share for the current fiscal year.

QGEN has been the topic of a number of recent analyst reports. BidaskClub lowered Qiagen from a hold rating to a sell rating in a research report on Thursday, September 13th. Morgan Stanley lifted their price objective on Qiagen from $37.00 to $38.00 and gave the stock an overweight rating in a research report on Wednesday, August 1st. Commerzbank reiterated a buy rating on shares of Qiagen in a research report on Wednesday, August 29th. Barclays reiterated a buy rating and issued a $43.00 price objective on shares of Qiagen in a research report on Thursday, September 6th. Finally, Deutsche Bank reiterated a buy rating on shares of Qiagen in a research report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $38.88.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Featured Story: Preferred Stock

Earnings History and Estimates for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply